Immuron Limited - Warrants (12/05/2022)
IMRNW
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.82M
Close$
Share Statistics
| Market cap | $27.82 Million |
|---|---|
| Enterprise Value | $18.80 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 4.88 |
| Outstanding Shares | 325,360,000 |
Return
| Return on Equity | -60.24% |
|---|---|
| Return on Assets | -51.03% |
| Return on Invested Capital | -68.03% |
Valuation & Multiples
| P/E Ratio | -3.49 |
|---|---|
| PEG | -8.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.7 |
| Enterprise Value to EBIT | -2.47 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Immuron Limited
7 employees
CEO: Steven George Lydeamore Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Re...